I Alex Bowman1, Alisha Bent2, Tri Le2, Alana Christie3, Zabi Wardak4, Yull Arriaga5, Kevin Courtney5, Hans Hammers5, Samuel Barnett6, Bruce Mickey7, Toral Patel6, Tony Whitworth6, Strahinja Stojadinovic8, Raquibul Hannan4, Lucien Nedzi8, Robert Timmerman4, James Brugarolas9. 1. Kidney Cancer Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX; Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX. Electronic address: isaac.bowman@utsouthwestern.edu. 2. Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX. 3. Kidney Cancer Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX. 4. Kidney Cancer Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX. 5. Kidney Cancer Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX; Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX. 6. Department of Neurological Surgery, UT Southwestern Medical Center, Dallas, TX. 7. Kidney Cancer Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX; Department of Neurological Surgery, UT Southwestern Medical Center, Dallas, TX. 8. Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX. 9. Kidney Cancer Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX; Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX. Electronic address: james.brugarolas@utsouthwestern.edu.
Abstract
BACKGROUND: Brain metastases (BM) occur frequently in patients with metastatic kidney cancer and are a significant source of morbidity and mortality. Although historically associated with a poor prognosis, survival outcomes for patients in the modern era are incompletely characterized. In particular, outcomes after adjusting for systemic therapy administration and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factors are not well-known. PATIENTS AND METHODS: A retrospective database of patients with metastatic renal cell carcinoma (RCC) treated at University of Texas Southwestern Medical Center between 2006 and 2015 was created. Data relevant to their diagnosis, treatment course, and outcomes were systematically collected. Survival was analyzed by the Kaplan-Meier method. Patients with BM were compared with patients without BM after adjusting for the timing of BM diagnosis, either prior to or during first-line systemic therapy. The impact of stratification according to IMDC risk group was assessed. RESULTS: A total of 56 (28.4%) of 268 patients with metastatic RCC were diagnosed with BM prior to or during first-line systemic therapy. Median overall survival (OS) for systemic therapy-naive patients with BM compared with matched patients without BM was 19.5 versus 28.7 months (P = .0117). When analyzed according to IMDC risk group, the median OS for patients with BM was similar for favorable- and intermediate-risk patients (not reached vs. not reached; and 29.0 vs. 36.7 months; P = .5254), and inferior for poor-risk patients (3.5 vs. 9.4 months; P = .0462). For patients developing BM while on first-line systemic therapy, survival from the time of progression did not significantly differ by presence or absence of BM (11.8 vs. 17.8 months; P = .6658). CONCLUSIONS: Survival rates for patients with BM are significantly better than historical reports. After adjusting for systemic therapy, the survival rates of patients with BM in favorable- and intermediate-risk groups were remarkably better than expected and not statistically different from patients without BM, though this represents a single institution experience, and numbers are modest.
BACKGROUND:Brain metastases (BM) occur frequently in patients with metastatic kidney cancer and are a significant source of morbidity and mortality. Although historically associated with a poor prognosis, survival outcomes for patients in the modern era are incompletely characterized. In particular, outcomes after adjusting for systemic therapy administration and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factors are not well-known. PATIENTS AND METHODS: A retrospective database of patients with metastatic renal cell carcinoma (RCC) treated at University of Texas Southwestern Medical Center between 2006 and 2015 was created. Data relevant to their diagnosis, treatment course, and outcomes were systematically collected. Survival was analyzed by the Kaplan-Meier method. Patients with BM were compared with patients without BM after adjusting for the timing of BM diagnosis, either prior to or during first-line systemic therapy. The impact of stratification according to IMDC risk group was assessed. RESULTS: A total of 56 (28.4%) of 268 patients with metastatic RCC were diagnosed with BM prior to or during first-line systemic therapy. Median overall survival (OS) for systemic therapy-naive patients with BM compared with matched patients without BM was 19.5 versus 28.7 months (P = .0117). When analyzed according to IMDC risk group, the median OS for patients with BM was similar for favorable- and intermediate-risk patients (not reached vs. not reached; and 29.0 vs. 36.7 months; P = .5254), and inferior for poor-risk patients (3.5 vs. 9.4 months; P = .0462). For patients developing BM while on first-line systemic therapy, survival from the time of progression did not significantly differ by presence or absence of BM (11.8 vs. 17.8 months; P = .6658). CONCLUSIONS: Survival rates for patients with BM are significantly better than historical reports. After adjusting for systemic therapy, the survival rates of patients with BM in favorable- and intermediate-risk groups were remarkably better than expected and not statistically different from patients without BM, though this represents a single institution experience, and numbers are modest.
Authors: Kenneth D Westover; J Travis Mendel; Tu Dan; Kiran Kumar; Ang Gao; Suprabha Pulipparacharuv; Puneeth Iyengar; Lucien Nedzi; Raquibul Hannan; John Anderson; Kevin S Choe; Wen Jiang; Ramzi Abdulrahman; Asal Rahimi; Michael Folkert; Aaron Laine; Chase Presley; C Munro Cullum; Hak Choy; Chul Ahn; Robert Timmerman Journal: Neuro Oncol Date: 2020-12-18 Impact factor: 12.300
Authors: Hiten D Patel; Nirmish Singla; Rashed A Ghandour; Yuval Freifeld; Joseph G Cheaib; Solomon L Woldu; Phillip M Pierorazio; Aditya Bagrodia Journal: Cancer Date: 2019-07-29 Impact factor: 6.860
Authors: Sebastian Rubino; Daniel E Oliver; Nam D Tran; Michael A Vogelbaum; Peter A Forsyth; Hsiang-Hsuan Michael Yu; Kamran Ahmed; Arnold B Etame Journal: Front Oncol Date: 2022-03-02 Impact factor: 6.244
Authors: Laurens V Beerepoot; Patrick E J Hanssens; Niels J van Ruitenbeek; Vincent K Y Ho; Hans M Westgeest Journal: J Neurooncol Date: 2021-06-25 Impact factor: 4.130